About Octant
Octant is a company based in Los Angeles (United States) founded in 2017. It operates as a HealthTech. Octant has raised $110 million across 4 funding rounds from investors including HHS, Allen & Company and Bristol-Myers Squibb. The company has 63 employees as of December 31, 2024. Octant offers products and services including OCT-980 and Genetic Disease Correctors. Octant operates in a competitive market with competitors including DNAnexus, Arbor Biotechnologies, Cytel, Verge Genomics and Singleron, among others.
- Headquarter Los Angeles, United States
- Employees 63 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Octant, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$110 M (USD)
in 4 rounds
-
Latest Funding Round
$80 M (USD), Series B
Apr 21, 2022
-
Investors
HHS
& 7 more
-
Employee Count
63
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Octant
Octant offers a comprehensive portfolio of products and services, including OCT-980 and Genetic Disease Correctors.
Designed to correct protein misfolding in retinal disorders.
Developed to address protein misfolding in genetic diseases.
People of Octant
Unlock access to complete
Unlock access to complete
Funding Insights of Octant
Octant has successfully raised a total of $110M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $80 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Octant
Octant has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Allen & Company and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Octant
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Octant
Investment portfolio details for Octant
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Octant
Detailed financials for Octant
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Octant Comparisons
Peer comparison for Octant
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Octant
Octant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Arbor Biotechnologies, Cytel, Verge Genomics and Singleron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease drugs are developed using computational genomics.
|
|
| Locked | Locked | Locked |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
Detailed competitors of Octant
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Octant
Complete news archive for Octant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Octant
Octant was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Octant is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Octant is a funded company, having raised a total of $110M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Octant is 63.
Octant is engaged in developing next-generation small molecule therapeutics by merging biology, chemistry, and computation. The company targets complex cellular mechanisms to address diseases caused by protein misfolding and mistrafficking. Solutions are built to deliver relief through innovative therapies, with a pipeline including treatments for retinitis pigmentosa, Fabry disease, and various cancers. Efforts are concentrated on precision medicine to transform drug discovery and clinical outcomes.
Octant's top competitors include DNAnexus, Arbor Biotechnologies and Cytel.
Octant offers OCT-980 and Genetic Disease Correctors.
Octant has 8 investors. Key investors include HHS, Allen & Company, Bristol-Myers Squibb, Catalio Capital Management, and Andreessen Horowitz.